From Cost Strategy to Long-Term Investment
Global Capability Centers (GCCs) are specialized units — a sort of digital twin — established by multinational corporations (MNCs) to manage critical business functions such as IT, ER&D, HR, Finance, and more. Global companies are setting up GCCs as a strategic investment that depends on the organization’s growth stage, operational needs, and digital transformation goals.
A GCC is more than just a cost-cutting strategy — it’s a long-term investment in operational agility, efficiency, innovation, and global scalability.
2.1 Key Drivers and Trends
MNCs could save 40–70% compared to onshore operations.
Access to a large, skilled talent pool, especially in STEM disciplines.
Proximity to emerging markets and customers across Asia-Pacific.
Tax incentives, SEZ benefits, and national skilling programs.
Ability to leverage digital transformation, AI, and R&D at scale.
Rise of managed models for faster setup, plus GenAI and blockchain integration.
2.2 Global GCC Landscape & Destination India
The global GCC market has witnessed strong and sustained growth over the past decade. Globally, GCCs contributed over $350 billion to the economy in 2024, reinforcing their importance as enablers of business resilience and growth. India remains a global leader, contributing $64.6 billion in GCC revenue, with projections to surpass $100 billion by 2030.
GCC Operating Models: Control vs. Speed
| Model | Description | Best For | Timeline |
|---|---|---|---|
| Captive GCCs | Direct ownership and control; maximum integration | Large global pharma with long-term India strategies | 9–18 months |
| Vendor-Managed Centers | Outsourced to IT/consulting partners; limited IP ownership | Companies seeking fastest time-to-operational | 6–9 months |
| Co-Sourced Centers | Shared responsibility between parent and partner firm | Mid-sized life sciences firms as a stepping stone to captive | ~12 months |
| COPO | Entity legally owned by global company, operations managed by partner. Speed, compliance, and flexibility. | Companies wanting control without full upfront investment | 12–24 months to captive |
This ecosystem-driven approach allows large pharma companies to set up at scale while also enabling mid-sized and smaller firms to de-risk entry and ramp up quickly — ensuring India remains accessible from global giants to emerging innovators.
Building Resilience While Scaling
While India’s Life Sciences GCCs have delivered standout successes, they continue to navigate talent, cultural, and regulatory challenges. India today hosts a vibrant mix of Life Sciences GCCs and GCC-like organizations, each contributing differently to the global pharma and biotech value chain.
4.1 GCCs — Captives / Global Pharma-Biopharma Centers
Global majors such as Novartis, GSK, Sanofi, Eli Lilly, AstraZeneca, BMS, and Pfizer have established fully owned centers across India. Novartis Hyderabad is one of the largest pharma GCCs in the world. GSK’s India GCC has begun housing critical global leadership roles — for example, the Global Head of Data Management — with full decision-making authority, marking a clear shift from when India-based positions were largely limited to support functions.
| Company | City | Est. | Size | Growth Trajectory | Type of Work / Focus | Strategic Role |
|---|---|---|---|---|---|---|
| Novartis | Hyderabad | 2000s+ | Large | Steady growth, expanded into AI & digital | Advanced analytics, drug dev, clinical ops | Global innovation hub, largest GCC |
| GSK | Bengaluru | 2021 | Medium | Consistent hiring; R&D team nearly double tech team | R&D, digital transformation, AI-enabled clinical ops | Supports global R&D integration & RWE |
| Sanofi | Hyderabad | 2023 | Medium | Rapid expansion; doubling planned by 2026 | Data analytics, R&D support, shared services | Strategic hub for global business services |
| Eli Lilly | Bengaluru | 2024 | Small→Med | High growth, clinical development focus | Clinical dev, biostats, regulatory, safety | Accelerates global drug development cycles |
| AstraZeneca | Chennai | 2023 | Medium | Scaling AI and digital health | Digital health platforms, AI trial design | Collaborates with academia on AI-driven health |
| BMS | Hyd / Blr | 2020 | Medium | Expanding digital health, enterprise IT | Clinical ops, digital health, enterprise IT | Oncology & cardiovascular program hub |
| Pfizer | Mumbai / Chennai | 2000s+ | Medium | Growing clinical/safety presence | Clinical trial mgmt, PV, regulatory | Key Asia hub for safety & clinical |
4.2 GCC-like — Analytics, Consulting, SaaS & Tech-Enabled Ops
Complementing Life Sciences GCCs are GCC-like players such as IQVIA, ZS Associates, and Axtria, which operate at the intersection of analytics, SaaS, and consulting. They support pharma clients globally with clinical trial management, commercial analytics, AI/ML platforms, and digital product development, and in many cases India is their largest innovation and delivery hub.
| Company | Cities | Est. | Size | Growth Trajectory | Focus | Strategic Role |
|---|---|---|---|---|---|---|
| IQVIA | Blr, Chennai, Gurugram | 2007+ | Large | Large, diversified LS presence | Clinical trial mgmt, PV, RWE, regulatory | Largest global delivery hub; end-to-end LS support |
| ZS Associates | Pune, Blr, Delhi | 2004+ | Medium | Strong growth in LS analytics | Commercial analytics, market access, AI marketing | Global analytics backbone for top pharma |
| Axtria | Gurugram, Noida, Blr | 2010s+ | Medium | Rapid scale-up, SaaS-driven innovation | AI/ML analytics, SaaS platforms | Product engineering & digital innovation hub |
4.3 Challenges & Mitigation Strategies
| Challenge | Mitigation Strategy |
|---|---|
| Talent & Attrition — high attrition due to competition from IT firms, startups, and other GCCs | Strengthen employer branding (e.g., Novartis positioning India as a strategic innovation hub); invest in structured career development (e.g., Sanofi’s leadership tracks in Hyderabad); enhance employee engagement through wellness and DEI initiatives. |
| Communication / Cultural Gaps — differences in communication styles affecting collaboration with global teams | Implement cultural agility training (e.g., GSK’s India GCC runs cross-cultural leadership workshops); rotate leadership roles across geographies (e.g., AstraZeneca’s global leadership rotations); embed mentoring programs connecting India teams with global HQ. |
| Regulatory & Compliance Complexity — dual compliance with Indian and international regulations slows operations | Engage proactively with regulators; invest in regulatory and compliance technologies and automation platforms; embed compliance-by-design frameworks early in project cycles. |
| Scaling Company Culture — maintaining a unified culture across global and India operations | Strengthen culture through regular leadership communication (e.g., ZS’s global townhalls); mentorship and peer coaching (e.g., Novartis); shared-value initiatives such as volunteering, community outreach, and sustainability programs. |
How India Fares Amid Emerging Global Hubs
India faces competition from hubs like Poland, Singapore, and Costa Rica, which offer attractive tax regimes and niche talent. Life Sciences GCCs in India are coping by building Centers of Excellence in data science, product innovation, and AI-based R&D.
- Poland has developed into a strong clinical operations and shared services hub for European pharma, particularly attractive for its EU regulatory alignment and multilingual workforce, but its talent pool is smaller.
- Singapore positions itself as an Asia-Pacific regional HQ and innovation hub, focusing on biotech R&D, regulatory affairs, and medtech manufacturing — yet high costs limit scale.
- Costa Rica has emerged as a niche hub for shared services and quality/regulatory functions, drawing U.S. pharma investment due to geographic proximity and bilingual talent, but it lacks the scale and scientific depth of India.
“Poland offers regulatory proximity, Singapore delivers innovation branding, Costa Rica provides nearshore convenience — but only India offers scale + science + digital at once.”
| Factor | India | Poland | Singapore | Costa Rica |
|---|---|---|---|---|
| Cost Advantage | High (30–40% lower than West) | Moderate | High cost | Moderate |
| Talent Depth | Very deep — biostats, PV, RWE, AI/ML | Strong multilingual clinical ops & shared services | Specialized in biotech, medtech, regulatory | Bilingual shared services & regulatory |
| Functional Breadth | End-to-end: Clinical, R&D, Regulatory, Digital, Shared Services | Clinical ops, regulatory, shared services | Regional HQ, R&D, regulatory affairs | Shared services, regulatory/quality |
| Strategic Role | Innovation, product ownership, global platforms | EU compliance, regional support | Innovation branding, APAC leadership | Mainly tactical regulatory support |
| Scale | Largest globally (100+ LS GCCs) | Mid-scale (dozens of GCCs) | Smaller scale due to costs | Small-to-mid scale |
Cementing Global Leadership
India’s ascent as a global hub for Life Sciences GCCs reflects the convergence of strong talent depth, digital expertise, and an enabling ecosystem of partners, government, and industry bodies. Over the past decade, global majors such as Sanofi, Novartis, GSK, AstraZeneca, and ZS Associates have evolved their India centers from back-office support to strategic hubs for innovation, clinical development, and digital transformation.
Yet, sustaining this momentum requires proactive policy support, ecosystem strengthening, and strategic foresight. India faces challenges such as high attrition in niche roles, policy uncertainty around data privacy, and competition from emerging hubs in Eastern Europe and Asia.
Recommendations
Build structured partnerships between GCCs, universities (IITs, NIPER, AIIMS), and skilling councils to align curricula with emerging needs such as biostatistics, RWE, AI in clinical trials, and digital pharmacovigilance. Invest in India-based leadership development programs to create a stronger pipeline of senior leaders capable of owning global product mandates.
Harmonize state-level incentives into a more predictable national framework. Implement clear data privacy, cross-border data transfer, and compliance guardrails that enable life sciences firms to confidently scale sensitive operations in India.
Accelerate the development of Tier-2 life sciences clusters (e.g., Pune, Kochi, Ahmedabad, Chandigarh) with targeted infrastructure, incubators, and connectivity. This will relieve cost/talent pressure in Bengaluru and Hyderabad while enhancing resilience and creating balanced growth.
Move the narrative from “cost efficiency” to “innovation leadership” by documenting and promoting success stories of global impact (AI-led clinical data sciences, digital therapeutics, pharmacovigilance automation). Encourage GCCs to co-create IP, patents, and regulated digital products out of India, elevating their global strategic role.
“India is already the world’s leading destination for Life Sciences GCCs. By addressing structural risks and seizing the opportunity to brand itself as a strategic, innovation-driven partner, India can cement its position as the backbone of global pharma and biotech transformation in the decade ahead.”
For many organizations, the question is no longer whether to build global capabilities, but how quickly and effectively they can do so.
Indeca GlobalHub Inc. is a US-based advisory and execution partner focused on helping companies design, build, and scale Global Capability Centers (GCCs) in India. This whitepaper reflects the collective research, insights, and on-the-ground experience of the Indeca GlobalHub team — practitioners who work daily at the intersection of global life sciences strategy and India execution.
The firm works with mid-sized and growth-stage organizations to enable scalable, efficient, and future-ready global operating models — from entity incorporation and compliance through talent ramp-up, infrastructure setup, and long-term operational maturity. Indeca GlobalHub brings a unique perspective: U.S.-based strategic oversight combined with deep India execution capability.
HQ: 1 Corporate Place South, Suite #120, Piscataway, NJ 08854, USA · India Hub: Gurugram, Haryana · www.indecaglobal.com · LinkedIn · sales@indecaglobal.com
Ready to build your GCC in India?
Schedule a no-obligation GCC Readiness Assessment with the Indeca GlobalHub team.
References
- NASSCOM Strategic Review 2025, Executive Summary.
- Inductus, Annual Report 2024 — A GCC Compendium.
- Healthark, Rise of Healthcare & Life Sciences GCCs in India, 2023.
- ANSR, State of Healthcare & Life Sciences GCCs in India, 2023.
- SRKay Consulting, Establishing a GCC in India Report.
- Inductus GCC Policies, 2024.
- NASSCOM Insights, GCC Trends and India’s Digital Economy.
- Industry reports and company disclosures: Novartis, GSK, Sanofi, AstraZeneca, Lilly, Pfizer, BMS.
- Everest Group, Global GCC Landscape Reports.
- Interviews and secondary research compiled from Economic Times, Business Standard, Mint.